Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.3.3.1 (
citrate synthase
)
4,488
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Human
HtrA2
is part of the HtrA family of ATP-independent serine proteases that are conserved in both prokaryotes and eukaryotes and localizes to the intermembrane space of the mitochondria. Several recent reports have suggested that
HtrA2
is important for maintaining proper mitochondrial homeostasis and may play a role in Alzheimer's disease (AD), which is characterized by the presence of aggregates of the amyloid-beta peptide 1-42 (Abeta1-42). In this study, we analyzed the ability of
HtrA2
to delay the aggregation of the model substrate
citrate synthase
(CS) and of the toxic Abeta1-42 peptide. We found that
HtrA2
had a moderate ability to delay the aggregation of CS in vitro, and this activity was significantly enhanced when the PDZ domain was removed suggesting an inhibitory role for this domain on the activity. Additionally, using electron microscopy and nuclear magnetic resonance analyses, we observed that
HtrA2
significantly delayed the aggregation of the Abeta1-42 peptide. Interestingly, the protease activity of
HtrA2
and its PDZ domain were not essential for the delay of Abeta1-42 peptide aggregation. These results indicate that besides its protease activity,
HtrA2
also performs a chaperone function and suggest a role for
HtrA2
in the metabolism of intracellular Abeta and in AD.
...
PMID:A new function of human HtrA2 as an amyloid-beta oligomerization inhibitor. 1950 9